File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trials

TitleEffects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trials
Authors
Issue Date2007
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2007, v. 5 n. 2, p. 178-185 How to Cite?
AbstractBackground & Aims: The aim of this study was to assess systematically the efficacy of proton pump inhibitors (PPIs) in the treatment of functional dyspepsia compared with placebo and to determine if any difference in the response exists between symptom subgroups of functional dyspepsia. Methods: A literature search was performed through September 2005 in PubMed, Medline, Embase, CINAHL, and Cochrane databases to include randomized, double-blind, placebo-controlled trials evaluating the efficacy of PPIs for the treatment of functional dyspepsia. Relative risk (RR) and relative risk reduction (RRR) and 95% confidence intervals (CI) were calculated under a random-effects model. Results: Seven studies with a total of 3725 patients were identified. PPIs were found to be more effective than placebo for reducing symptoms in patients with functional dyspepsia (RRR, 10.3%; 95% CI, 2.7%-17.3%). The estimated number needed to treat is 14.6 (95% CI, 8.7-57.1). When stratified analyses were performed, a significant difference in the efficacy was observed only in patients with ulcer-like (RRR, 12.8%; 95% CI, 7.2%-18.1%) and reflux-like dyspepsia (RRR, 19.7%; 95% CI, 1.8%-34.3%), but not in those with dysmotility-like (RRR, 5.1%; 95% CI, -10.9% to 18.7%) and unspecified dyspepsia (RRR, -8.0%; 95% CI, -23.7% to 5.6%). The effect of H pylori on the efficacy of PPIs remains unclear. Significant heterogeneity among studies was found for the overall analysis, dysmotility-like dyspepsia, H pylori-negative subgroup, and different dose subgroups. Conclusions: PPIs are more effective than placebo for the management of patients with ulcer-like and reflux-like functional dyspepsia. © 2007 AGA Institute.
Persistent Identifierhttp://hdl.handle.net/10722/163060
ISSN
2015 Impact Factor: 7.68
2015 SCImago Journal Rankings: 2.744
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWang, WHen_HK
dc.contributor.authorHuang, JQen_HK
dc.contributor.authorZheng, GFen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLiu, XGen_HK
dc.contributor.authorKarlberg, Jen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2012-09-05T05:27:06Z-
dc.date.available2012-09-05T05:27:06Z-
dc.date.issued2007en_HK
dc.identifier.citationClinical Gastroenterology And Hepatology, 2007, v. 5 n. 2, p. 178-185en_HK
dc.identifier.issn1542-3565en_HK
dc.identifier.urihttp://hdl.handle.net/10722/163060-
dc.description.abstractBackground & Aims: The aim of this study was to assess systematically the efficacy of proton pump inhibitors (PPIs) in the treatment of functional dyspepsia compared with placebo and to determine if any difference in the response exists between symptom subgroups of functional dyspepsia. Methods: A literature search was performed through September 2005 in PubMed, Medline, Embase, CINAHL, and Cochrane databases to include randomized, double-blind, placebo-controlled trials evaluating the efficacy of PPIs for the treatment of functional dyspepsia. Relative risk (RR) and relative risk reduction (RRR) and 95% confidence intervals (CI) were calculated under a random-effects model. Results: Seven studies with a total of 3725 patients were identified. PPIs were found to be more effective than placebo for reducing symptoms in patients with functional dyspepsia (RRR, 10.3%; 95% CI, 2.7%-17.3%). The estimated number needed to treat is 14.6 (95% CI, 8.7-57.1). When stratified analyses were performed, a significant difference in the efficacy was observed only in patients with ulcer-like (RRR, 12.8%; 95% CI, 7.2%-18.1%) and reflux-like dyspepsia (RRR, 19.7%; 95% CI, 1.8%-34.3%), but not in those with dysmotility-like (RRR, 5.1%; 95% CI, -10.9% to 18.7%) and unspecified dyspepsia (RRR, -8.0%; 95% CI, -23.7% to 5.6%). The effect of H pylori on the efficacy of PPIs remains unclear. Significant heterogeneity among studies was found for the overall analysis, dysmotility-like dyspepsia, H pylori-negative subgroup, and different dose subgroups. Conclusions: PPIs are more effective than placebo for the management of patients with ulcer-like and reflux-like functional dyspepsia. © 2007 AGA Institute.en_HK
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_HK
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_HK
dc.subject.meshAnti-Ulcer Agents - Therapeutic Useen_US
dc.subject.meshDyspepsia - Drug Therapyen_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHumansen_US
dc.subject.meshProton Pumps - Antagonists & Inhibitorsen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.titleEffects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trialsen_HK
dc.typeArticleen_HK
dc.identifier.emailKarlberg, J: jpekarl@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityKarlberg, J=rp00400en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.cgh.2006.09.012en_HK
dc.identifier.pmid17174612-
dc.identifier.scopuseid_2-s2.0-33846805724en_HK
dc.identifier.hkuros131405-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846805724&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue2en_HK
dc.identifier.spage178en_HK
dc.identifier.epage185en_HK
dc.identifier.isiWOS:000244511700010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWang, WH=23390847100en_HK
dc.identifier.scopusauthoridHuang, JQ=7403635051en_HK
dc.identifier.scopusauthoridZheng, GF=7402224500en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridLiu, XG=26643623200en_HK
dc.identifier.scopusauthoridKarlberg, J=7005218406en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats